Lando & Anastasi, LLP
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
The Trustees of the University of Pennsylvania Novartis AG
A C C C A C A C A A A A C C A A A A
A61K C07K C07K C07K A61K C07K A61K C07K A61K A61K A61P A61P C07K C07K A61P A61K A61K A61K
inventional inventional inventional inventional inventional additional additional additional inventional inventional inventional inventional inventional additional inventional additional additional additional
Na Hans Ju Young Thai Li Ming Naveen Kumar Barbara Carl H. Elena Andreas Lu Jimin Saar Jennifer Jennifer Mary Steven Marco
Li Bitter Kim Tran Zhou Lei Dakappagari Brannetti June Orlando Loew Huang Zhang Gill Brogdon Bordeaux Highfill Ruella